TBI/fludarabine versus busulfan/fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allo-HCT. A study from the ALWP of the EBMT

Swoboda, R.Labopin, M.Giebel, S.Schroeder, T.Kroeger, N.Arat, M.Savani, B.Spyridonidis, A.Hamladji, R. M.Potter, V.Deconinck, E.Yakoub-Agha, I.Rambaldi, A.Ozdogu, H.Sanz, J.Nagler, A.Mohty, M.2023-01-042023-01-0420220268-3369http://hdl.handle.net/11727/8549enginfo:eu-repo/semantics/closedAccessTBI/fludarabine versus busulfan/fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allo-HCT. A study from the ALWP of the EBMTconferenceObject57Supplement 13535000878153300055